KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Non-Current Assets (2016 - 2025)

Alnylam Pharmaceuticals' Other Non-Current Assets history spans 13 years, with the latest figure at $59.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 8.96% year-over-year to $59.5 million; the TTM value through Dec 2025 reached $59.5 million, down 8.96%, while the annual FY2025 figure was $59.5 million, 8.96% down from the prior year.
  • Other Non-Current Assets reached $59.5 million in Q4 2025 per ALNY's latest filing, up from $55.8 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $92.7 million in Q2 2023 to a low of $34.6 million in Q2 2021.
  • Average Other Non-Current Assets over 5 years is $63.5 million, with a median of $64.4 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 124.23% in 2021, then dropped 28.06% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $60.2 million in 2021, then increased by 9.78% to $66.1 million in 2022, then dropped by 6.34% to $61.9 million in 2023, then increased by 5.51% to $65.3 million in 2024, then decreased by 8.96% to $59.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Other Non-Current Assets are $59.5 million (Q4 2025), $55.8 million (Q3 2025), and $57.2 million (Q2 2025).